<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27801" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Prolactinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yatavelli</surname>
            <given-names>Rajini Kanth R.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhusal</surname>
            <given-names>Kamal</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rajini Kanth Yatavelli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamal Bhusal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27801.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Prolactin-secreting tumors of the pituitary gland, also known as prolactinomas, are the most common secretory tumors of the pituitary gland, accounting for up to 40 percent of pituitary adenomas. Prolactinomas can lead to a wide variety of symptoms, either due to mass effect or hypersecretion of prolactin. This activity illustrates the evaluation, treatment, and complications of prolactinomas and the importance of an interprofessional team approach to its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the common presentations of prolactinomas.</p></list-item><list-item><p>Outline the evaluation of prolactinomas.</p></list-item><list-item><p>Review the management of prolactinomas.</p></list-item><list-item><p>Explain the role of collaboration among interprofessional team members to improve care coordination and minimize oversight, leading to earlier diagnosis and treatment and better outcomes for patients with prolactinomas.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27801&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27801">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27801.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Prolactin-secreting tumors of the pituitary gland&#x000a0;are called prolactinomas. It is the most common secretory tumor of the pituitary gland accounting for up to&#x000a0;40% of total pituitary adenomas. Prolactinomas cause a wide variety of symptoms, either due to mass effect of the tumor or due to hypersecretion of prolactin. Based on the size of the tumors, prolactinomas can be classified as micro prolactinoma (smaller than 10 mm), macroprolactinoma (larger than 10 mm), or giant prolactinoma (larger than 4 cm). Hyperprolactinemia is not always due to prolactinoma, and other causes like pregnancy, drugs, hypothyroidism, and pituitary stalk effect due to other pituitary tumors should be considered in the differential.&#x000a0;<xref ref-type="bibr" rid="article-27801.r1">[1]</xref><xref ref-type="bibr" rid="article-27801.r2">[2]</xref></p>
      </sec>
      <sec id="article-27801.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact cause of prolactinoma is poorly understood. Prolactinomas arise from monoclonal expansion of pituitary lactotrophs that have undergone somatic mutation. Pituitary tumor transforming gene&#x000a0;<italic toggle="yes">(PTTG</italic>) overexpression and mutation of a receptor of fibroblast growth factor 4&#x000a0;<italic toggle="yes">(FGF4)</italic>&#x000a0;have been found in pituitary adenoma, mainly prolactinoma. Most prolactinomas are sporadic in origin&#x000a0;but can also occur as part of familial syndromes. Familial isolated prolactinoma and other pituitary adenomas have been described. It can be a part of multiple endocrine neoplasia type 1 <italic toggle="yes">(MEN1</italic>); up to 15 to 60% of patients with&#x000a0;<italic toggle="yes">MEN1</italic> can have a pituitary adenoma, and the majority of them are prolactinomas.<xref ref-type="bibr" rid="article-27801.r3">[3]</xref><xref ref-type="bibr" rid="article-27801.r4">[4]</xref></p>
      </sec>
      <sec id="article-27801.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Prolactinomas account for up to 40% of all clinically recognized pituitary adenomas. The mean prevalence of prolactinoma is estimated to be approximately 10 per 100,000 in men and 30 per 100,000 in women, with a peak prevalence in women aged 25 to 34 years. Among patients with prolactinomas, as many as 60% of the males present with macroprolactinomas, while 90% of the females present with microprolactinomas.</p>
      </sec>
      <sec id="article-27801.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Prolactinomas arise from monoclonal expansion of pituitary lactotrophs and are mostly benign, often sharply demarcated without evidence of invasion. A few prolactinomas could behave aggressively with the invasion of surrounding local structures, and they generally&#x000a0;have higher mitotic activity and are more cellular and pleomorphic. Distance extracranial involvement is required to be called a malignant prolactinoma. Lateral parts of the anterior pituitary are the most common sites involved with prolactinoma.<xref ref-type="bibr" rid="article-27801.r5">[5]</xref></p>
        <p>Rarely mixed tumors that secrete growth hormone and prolactin, adrenocorticotropic hormone (ACTH), and prolactin or thyroid stimulating hormone (TSH) and prolactin can also be seen, which is recognized with immunohistochemistry.&#x000a0;</p>
        <p>Microadenomas (smaller than 1 cm) usually are confined&#x000a0;to sella turcica and do not cause any compressive symptoms, but macroadenomas (greater than 1 cm) can expand to an adjacent structure like optic chiasm, cavernous sinuses and causes various compressive symptoms like visual field defects, cranial nerve palsy, and headaches. Symptoms of microadenoma are mainly due to elevated levels of prolactin.</p>
        <p>Prolactin levels are usually directly proportionate to the size of the tumor, ranging from below 200 ng/ml with less than 1 cm, 200&#x000a0;ng/ml&#x000a0;to 1000 ng/ml with 1 cm to 2 cm, and more than 1000 ng/ml with tumor sized more than 2 cm in diameter. If prolactin level does not match with tumor size, then it can be either&#x000a0;due to not well-differentiated prolactinoma or the presence of a large cystic component in the tumor.</p>
        <p>Hypothalamus has a predominant inhibitory influence on prolactin secretion via dopamine, and any factor which disrupts this mechanism causes hyperprolactinemia. It is important to consider the various causes of hyperprolactinemia, as increased prolactin secretion is noted in many physiological and pathological states other than prolactinomas.</p>
      </sec>
      <sec id="article-27801.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Prolactinomas clinically present because of the mass effect of the tumor or because of hyperprolactinemia. Microprolactinomas (less than 1 cm) can present with symptoms of hyperprolactinemia or are detected incidentally on neuroimaging done for other reasons. Macroprolactinomas, on the other hand, present with mass effects on the surrounding structures.</p>
        <p>
<bold>Signs and Symptoms Due to Mass Effect</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Headaches</p>
          </list-item>
          <list-item>
            <p>Vision changes-visual field deficits, blurred vision, decreased visual acuity</p>
          </list-item>
          <list-item>
            <p>Cranial nerve palsies-especially with invasive tumors or with pituitary apoplexy</p>
          </list-item>
          <list-item>
            <p>Seizures, hydrocephalus, and unilateral exophthalmos are rare presentations</p>
          </list-item>
          <list-item>
            <p>Pituitary apoplexy is a medical emergency because of spontaneous hemorrhage into the pituitary tumor and presents with severe headaches, vision changes, and panhypopituitarism.</p>
          </list-item>
        </list>
        <p>
<bold>Signs and Symptoms Due to Hyperprolactinemia</bold>
</p>
        <p>
<bold>Males</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Decreased libido</p>
          </list-item>
          <list-item>
            <p>Impotence</p>
          </list-item>
          <list-item>
            <p>Erectile dysfunction</p>
          </list-item>
          <list-item>
            <p>Oilgozoospermia (due to secondary hypogonadism)</p>
          </list-item>
        </list>
        <p>
<bold>Females</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Oligomenorrhea, amenorrhea</p>
          </list-item>
          <list-item>
            <p>Infertility, loss of libido</p>
          </list-item>
          <list-item>
            <p>Galactorrhea</p>
          </list-item>
        </list>
        <p>
<bold>Children and Adolescents</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Growth arrest</p>
          </list-item>
          <list-item>
            <p>Pubertal delay</p>
          </list-item>
          <list-item>
            <p>Primary amenorrhea</p>
          </list-item>
        </list>
        <p>Other features like osteopenia, anxiety, depression, fatigue, and emotional instability can be seen in both sexes. About 10% of prolactinomas can be co-secreting growth hormone, so gigantism/acromegaly can be seen in those patients.</p>
      </sec>
      <sec id="article-27801.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>An extensive history and physical examination are needed to exclude other causes of hyperprolactinemia and to document any visual field deficits, galactorrhea, growth changes, hypopituitarism, menstrual irregularities, impotence, infertility. Formal visual field testing by an ophthalmologist should be done, especially for macroadenomas.&#x000a0;<xref ref-type="bibr" rid="article-27801.r6">[6]</xref><xref ref-type="bibr" rid="article-27801.r7">[7]</xref><xref ref-type="bibr" rid="article-27801.r8">[8]</xref>&#x000a0;The following differential diagnosis should be considered during evaluation:</p>
        <p>
<bold>Physiological Causes:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Nipple stimulation in lactating&#x000a0;women</p>
          </list-item>
          <list-item>
            <p>Stress</p>
          </list-item>
        </list>
        <p>
<bold>Pathological Causes:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Hypothalamic disorders</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>&#x000a0;Craniopharyngiomas, meningioma, dysgerminoma</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Non-secreting pituitary adenoma</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Sarcoidosis; Histiocytosis X</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Cranial irradiation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Pituitary disorders</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>Prolactinoma</p>
          </list-item>
          <list-item>
            <p>Acromegaly/Cushing disease</p>
          </list-item>
          <list-item>
            <p>Empty Sella syndrome</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Lymphocytic hypophysitis&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drugs (Dopamine antagonists)</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>Antipsychotics</p>
          </list-item>
          <list-item>
            <p>Tricyclic antidepressants; SSRI</p>
          </list-item>
          <list-item>
            <p>Antiemetic: Metoclopramide, domperidone, prochlorperazine</p>
          </list-item>
          <list-item>
            <p>Antihypertensive: Verapamil, alpha-methyldopa&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Opioid analgesics: Morphine, methadone,&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Idiopathic hyperprolactinemia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27801.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Laboratory</bold>
</p>
        <p>The test begins with serum prolactin level. If the prolactin level is high, a comprehensive metabolic panel, TSH, and a pregnancy test (for women of childbearing age) should be&#x000a0;obtained. Assessment of other pituitary hormones, including cortisol, ACTH, IGF-1, LH, FSH, and testosterone/estradiol, should be done based on age and gender to exclude any hypopituitarism or other co-secreting tumors.<xref ref-type="bibr" rid="article-27801.r9">[9]</xref><xref ref-type="bibr" rid="article-27801.r10">[10]</xref><xref ref-type="bibr" rid="article-27801.r11">[11]</xref></p>
        <p>Patients can have very&#x000a0;high prolactin levels; however, when measured, they can be reported as falsely low due to a phenomenon called the &#x0201c;Hook effect.&#x0201d; When there is a suspicion, serial dilution of the serum sample and re-measuring the prolactin levels will be helpful.</p>
        <p>Another condition where measured prolactin can be high, although true prolactin level is low, is when patients have higher molecular weight prolactin called macroprolactin. Macroprolactin levels should be obtained in asymptomatic hyperprolactinemia. The laboratory can pretreat the serum with polyethylene glycol to precipitate the macroprolactin before the immunoassay for prolactin.</p>
        <p>
<bold>Imaging</bold>
</p>
        <p>CT scan may demonstrate the mass, but MRI with gadolinium is the preferred imaging modality for evaluation of hyperprolactinemia as it best describes the anatomy of the hypothalamic-pituitary area. All patients with tumors adjacent to or compressing to optic chiasm should be referred for formal visual field testing<bold><bold>.</bold></bold></p>
        <p>
<bold>Treatment/Management</bold>
</p>
        <p>Macroprolactinomas incidentally discovered without symptoms can be observed with periodic monitoring of the labs and imaging.<xref ref-type="bibr" rid="article-27801.r12">[12]</xref><xref ref-type="bibr" rid="article-27801.r13">[13]</xref></p>
        <p>Macroprolactinoma or symptomatic microadenoma should be treated with dopamine agonist therapy. The goals of treatment would be tumor shrinkage, restoration of visual fields if any defect, reversal of galactorrhea, and restoration of fertility or abnormal sexual function. Cabergoline is preferred due to a higher frequency in normalizing the prolactin level and tumor shrinkage. Amenorrhea caused by macroprolactinoma can be treated with oral contraceptives if fertility is not desired without dopamine agonists.</p>
        <p>Most prolactinomas are managed with medical therapy only with surgery and radiotherapy reserved for refractory cases.</p>
        <p>
<bold>Medical Therapy</bold>
</p>
        <p>Unlike other pituitary tumors, the preferred treatment for prolactinomas is medical therapy. Oral contraceptives alone can be given if the only symptoms are amenorrhea and or osteoporosis. Specific treatment for prolactinomas is one of the dopamine agonists.</p>
        <p>Cabergoline and bromocriptine are two commonly used dopamine agonists. Pergolide is withdrawn from the market due to concerns about valvular heart disease, and quinagolide is not available in the United States. Dopamine agonists suppress the synthesis and release of prolactin and lactotroph cellular proliferation, causing shrinkage of the tumor. They can cause nausea and dizziness.</p>
        <p>Bromocriptine is preferred during pregnancy if needed due to more available data than cabergoline. It is also cheaper but has more side effects than cabergoline, like nausea, vomiting, nasal stuffiness, and postural hypotension. It is started at 1.25 mg at bedtime or after dinner daily for one week, then increased to 1.25 mg 2 times a day (after breakfast and dinner). The dose should be increased every 4 weeks if the prolactin level is not normalized up to a maximum dose of 5 mg two times a day.&#x000a0; If bromocriptine is unsuccessful, cabergoline should be started.</p>
        <p>Treatment with&#x000a0;dopamine&#x000a0;agonist should be tapered and stopped if prolactin level is normal and the tumor is not visible in MRI after at least two years of treatment.</p>
        <p>Estrogen replacement is an option for a woman with inadequate response to treatment and not desiring fertility. For a man with inadequate treatment response, testosterone therapy (if no fertility is desired) or human chorionic gonadotropin (if fertility is desired) should be started.</p>
        <p>
<bold>Surgery</bold>
</p>
        <p>Transsphenoidal surgery is the preferred surgical option if surgery is indicated for the following reasons:</p>
        <list list-type="bullet">
          <list-item>
            <p>Unsuccessful medical therapy to lower prolactin level and decrease tumor size after several months of maximum dose.</p>
          </list-item>
          <list-item>
            <p>A woman with large prolactinoma (more than 3 cm) wishes to become pregnant as it can get larger during pregnancy.</p>
          </list-item>
          <list-item>
            <p>Radiation therapy should be considered for residual tumors after surgery and resistance to cabergoline therapy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27801.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Renal failure</p>
          </list-item>
          <list-item>
            <p>Breast stimulation</p>
          </list-item>
          <list-item>
            <p>Pituitary tumors</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27801.s10" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Mass effect leading to visual deficits, cranial nerve palsies, or pituitary apoplexy</p>
          </list-item>
          <list-item>
            <p>Infertility</p>
          </list-item>
          <list-item>
            <p>Osteoporosis</p>
          </list-item>
          <list-item>
            <p>Complications related to surgery may include vision loss, CSF leak, permanent hypopituitarism</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27801.s11" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>Neurosurgeon</p>
          </list-item>
          <list-item>
            <p>Radiation oncologist</p>
          </list-item>
          <list-item>
            <p>Endocrinologist</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27801.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Usually, in pregnancy, there is hyperplasia of pituitary lactotrophs, and prolactin levels increase. Prolactinomas increase in size during pregnancy, and in patients with known macroadenomas, one can consider surgery before pregnancy, or those on medical therapy should be monitored carefully with periodic visual field testing. Bromocriptine has the largest safety database in pregnancy and is the preferred drug during pregnancy.</p>
        <p>Pituitary apoplexy is an endocrine emergency when there is spontaneous hemorrhage into the pituitary adenoma/prolactinoma and patients present with sudden onset headaches and vision changes. Any patient with known prolactinoma/pituitary adenoma presenting with the above symptoms would need an urgent MRI and neurosurgical/endocrine evaluation.</p>
      </sec>
      <sec id="article-27801.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Once a prolactinoma has been diagnosed, patient education is key to preventing high morbidity. All patients must be closely followed, and patients must be educated about the symptoms of prolactinoma and when to seek help. If the decision is made to taper or withdraw medical therapy, the patient must undergo imaging studies periodically to monitor for recurrence of growth. The pharmacist should educate the patient on drugs used to treat prolactinomas and their adverse effects. Finally, the oncology nurse should educate the patient on the possibility of radiation therapy for large lesions and the possibility of hypopituitarism.<xref ref-type="bibr" rid="article-27801.r14">[14]</xref><xref ref-type="bibr" rid="article-27801.r15">[15]</xref>&#x000a0;{Level 5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>The majority of patients with microprolactinomas&#x000a0;have an excellent prognosis. These patients can be managed medically for extended periods. Macroprolactinomas, on the other hand, can grow over time and require more aggressive treatment. The growth rate of macroprolactinomas is unpredictable, and the patient must be closely followed up.&#x000a0;The&#x000a0;decision to taper medical therapy requires sound judgment because the tumor can grow&#x000a0;in size without treatment. <xref ref-type="bibr" rid="article-27801.r16">[16]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-27801.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27801&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27801">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/prolactinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27801">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27801/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27801">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27801.s15">
        <fig id="article-27801.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Prolactinoma MRI Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="prolactinoma1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27801.s16">
        <title>References</title>
        <ref id="article-27801.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pekic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soldatovic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miljic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stojanovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doknic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petakov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Popovic</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Familial Cancer Clustering in Patients with Prolactinoma.</article-title>
            <source>Horm Cancer</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-50</page-range>
            <pub-id pub-id-type="pmid">30196424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Greenman</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Dopamine Agonists for Pituitary Adenomas.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>469</fpage>
            <pub-id pub-id-type="pmid">30186234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ara&#x000fa;jo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.</article-title>
            <source>Endocrine</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>470</fpage>
            <page-range>470-476</page-range>
            <pub-id pub-id-type="pmid">30088141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atluri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarathi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boppana</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shivaprasad</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Etiological Profile of Galactorrhoea.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>489</fpage>
            <page-range>489-493</page-range>
            <pub-id pub-id-type="pmid">30148095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saleem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-16</page-range>
            <pub-id pub-id-type="pmid">30072818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maldaner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tschopp</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bozinov</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Regli</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Modern Management of Pituitary Adenomas - Current State of Diagnosis, Treatment and Follow-Up].</article-title>
            <source>Praxis (Bern 1994)</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>107</volume>
            <issue>15</issue>
            <fpage>825</fpage>
            <page-range>825-835</page-range>
            <pub-id pub-id-type="pmid">30043702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bettencourt-Silva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Magalh&#x000e3;es</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Queir&#x000f3;s</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves' Disease-Report of a Challenging Case and Literature Review.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>312</fpage>
            <pub-id pub-id-type="pmid">29928263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krajewski</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Rotermund</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flitsch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pituitary adenomas in children and young adults.</article-title>
            <source>Childs Nerv Syst</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>1691</fpage>
            <page-range>1691-1696</page-range>
            <pub-id pub-id-type="pmid">29850940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vilar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abucham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Albuquerque</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Araujo</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Azevedo</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Boguszewski</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Casulari</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Cunha Neto</surname>
                <given-names>MBC</given-names>
              </name>
              <name>
                <surname>Czepielewski</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>FHG</given-names>
              </name>
              <name>
                <surname>Faria</surname>
                <given-names>MDS</given-names>
              </name>
              <name>
                <surname>Gadelha</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Garmes</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Glezer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gurgel</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jallad</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>PAC</given-names>
              </name>
              <name>
                <surname>Montenegro</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Musolino</surname>
                <given-names>NRC</given-names>
              </name>
              <name>
                <surname>Naves</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Ribeiro-Oliveira J&#x000fa;nior</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>CMS</given-names>
              </name>
              <name>
                <surname>Viecceli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bronstein</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.</article-title>
            <source>Arch Endocrinol Metab</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>236</fpage>
            <page-range>236-263</page-range>
            <pub-id pub-id-type="pmid">29768629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakhleh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shehadeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zloczower</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zolotov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Daoud Naccache</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Management of cystic prolactinomas: a review.</article-title>
            <source>Pituitary</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>425</fpage>
            <page-range>425-430</page-range>
            <pub-id pub-id-type="pmid">29654440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beshyah</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sherif</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Chentli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hamrahian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Raef</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>El-Fikki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jambart</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of prolactinomas: a survey of physicians from the Middle East and North Africa.</article-title>
            <source>Pituitary</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <page-range>231-240</page-range>
            <pub-id pub-id-type="pmid">27783196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maiter</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Current Challenges in the Management of Prolactinomas.</article-title>
            <source>Eur Endocrinol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-40</page-range>
            <pub-id pub-id-type="pmid">29632566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salazar-L&#x000f3;pez-Ortiz</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Bueno</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-B&#x000e1;rcena</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Gamboa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ortiz-Plata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porias-Cu&#x000e9;llar</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Rembao-Boj&#x000f3;rquez</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Sandoval-Huerta</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Tapia-Serrano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez-Castillo</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Vital-Reyes</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>[Clinical practice guideline for the diagnosis and treatment of hyperprolactinemia].</article-title>
            <source>Ginecol Obstet Mex</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-42</page-range>
            <pub-id pub-id-type="pmid">24779268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langlois</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McCartney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fleseriu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recent Progress in the Medical Therapy of Pituitary Tumors.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-170</page-range>
            <pub-id pub-id-type="pmid">28685507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuny</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barlier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feelders</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weryha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Ferone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gatto</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-58</page-range>
            <pub-id pub-id-type="pmid">25556152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27801.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rutkowski</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Aghi</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes.</article-title>
            <source>Expert Rev Endocrinol Metab</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-33</page-range>
            <pub-id pub-id-type="pmid">30063440</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
